A carregar...
Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy
PURPOSE: Immunotherapy is a standard of care for children with high-risk neuroblastoma, where bone marrow (BM) is the predominant metastatic site. Early response markers of minimal residual disease (MRD) in the BM that are also predictive of survival could help individualize patient therapies. PATIE...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4334779/ https://ncbi.nlm.nih.gov/pubmed/25559819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.6777 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|